After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
A triplet did worse than control in first-line kidney cancer.
The FDA will rule on a low dose of zongertinib in the summer.
US approval could mark the company's graduation to oncology.
Meanwhile, Tango tries again in PRMT5.
Halda, Accent and Vividion take more projects into phase 1.
